Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 6, 2006, Pages 1215-1220

  Chierakul, Wirongrong ^a   Wangboonskul, Jinda ^b   Singtoroj, Thida ^a   Pongtavornpinyo, Wirichada ^a   Short, Jennifer M ^a,c   Maharjan, Bina ^a   Wuthiekanun, Vanaporn ^a   Dance, David A B ^d   Teparrukkul, Prapit ^e   Lindegardh, Niklas ^a,c   Peacock, Sharon J ^a,c   Day, Nicholas P ^a,c   Chaowagul, Wipada ^e   White, Nicholas J ^a,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Sappasitthiprasong Hospital   (Thailand)

Author keywords

Amoxicillin; Burkholderia pseudomallei; Clavulanate; Monte Carlo simulation; PK PD

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID;

ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; GROWTH INHIBITION; HUMAN; MELIOIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CLAVULANIC ACID; HUMANS; MELIOIDOSIS; MIDDLE AGED; TIME FACTORS;

EID: 33845357081     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl389     Document Type: Article

References (15)

1. White NJ. Melioidosis. Lancet 2003; 361: 1715-22.
2. Chaowagul W, Chierakul W, Simpson AJ et al. An open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy in melioidosis. Antimicrob Agents Chemother 2005; 49: 4020-5.
3. Rajchanuvong A, Chaowagul W, Suputtamongkol Y et al. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1995; 89: 546-9.
4. Dance DA, Wuthiekanun V, Chaowagul W et al. The activity of amoxycillin/ clavulanic acid against Pseudomonas pseudomallei. J Antimicrob Chemother 1989; 24: 1012-4.
5. Tamamoto T, Naigowit P, Deisirilert S et al. In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 2027-9.
6. Suputtamongkol Y, Rajchanuwong A, Chaowagul W et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19: 846-53.
7. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 2002; 19: 333-9.
8. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 Suppl 1: S13-S20.
9. Walsh AL, Smith MD, Wuthiekanun V et al. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomaller. evaluation of current treatment. Antimicrob Agents Chemother 1995; 39: 2356-8.
10. Calver AD, Walsh NS, Quinn PF et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24: 570-4.
11. White AR, Kaye C, Poupard J et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 Suppl S1: 13-20.
12. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 2004; 48: 2464-70.
13. Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 2003; 9:292-6.
14. Lindegardh N, Singtoroj T, Annerberg A et al. Development and validation of a solid-phase extraction-liquid chromatographic method for determination of amoxicillin in plasma. Ther Drug Monit 2005; 27: 503-8.
15. Kaye CM, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23: 578-84.